Key result
TMAO exacerbated doxorubicin-induced cardiac dysfunction and fibrosis in mice through activation of the NLRP3 inflammasome.
Why the study?
Although gut microbiota-derived TMAO is linked to cardiac fibrosis and NLRP3 inflammasome activation contributes to fibrosis, whether TMAO mediates cardiac fibrosis via activating the NLRP3 inflammasome remains unclear.
TMAO exacerbates doxorubicin-induced cardiac fibrosis and dysfunction through activation of the NLRP3 inflammasome, highlighting a potential therapeutic target for preventing cardiac fibrosis.
Answers are grounded in this paper and cite their sources.
Should not yet change doxorubicin management; hypothesis-generating for TMAO-NLRP3 targeting in cardiotoxicity.
Background/Aims: Gut microbiota has been reported to correlate with a higher mortality and worse prognosis of cardiovascular diseases. Trimethylamine N-oxide (TMAO) is a gut microbiota-dependent metabolite of specific dietary nutrients, which is linked to cardiac fibrosis. Recent reports have suggested that the activation of Nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome contributed to cardiac fibrosis. However, whether TMAO mediates cardiac fibrosis via activating NLRP3 inflammasome remains unclear. Methods and Results: To determine the role of TMAO–mediated cardiac fibrosis, we established mouse models of doxorubicin (DOX)-induced cardiac fibrosis with or without TMAO in drinking water. TMAO exacerbated DOX-induced cardiac dysfunction, heart weight and cardiac fibrosis manifested by enhanced collagen accumulation, higher profibrotic levels and elevated inflammatory factors as well as NLRP3 inflammasome activation. Using primary cultured mouse cardiac fibroblast, our results indicated that TMAO promoted proliferation, migration and collagen secretion in a dose-dependent manner by TGF-β/Smad3 signaling. Furthermore, TMAO treatment induced NLRP3 inflammasome activation including oxidative stress in cultured cardiac fibroblast. Importantly, the silencing of NLRP3 presented a protection effect against cardiac fibrosis including cellular proliferation, migration and collagen deposition in vitro. Conclusions: Our data suggested that TMAO aggravated DOX-induced mouse cardiac fibrosis, at least in part, through activation of the NLRP3 inflammasome, providing a new potential target for preventing the progression of cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied Cardiac fibrosis (n=40). Trimethylamine N-Oxide (TMAO) vs. Control (PBS) or Doxorubicin alone was evaluated on Cardiac dysfunction and fibrosis (ejection fraction, fractional shortening, collagen accumulation). TMAO exacerbated doxorubicin-induced cardiac dysfunction and fibrosis in mice through activation of the NLRP3 inflammasome.
Synapse has enriched 10 related papers. Consider them for comparative context: